

AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraphs beginning at page 80, line 11, as follows:

AVCBSPantitrypsinGAAG-delta preparation strategy. The plasmid AVCBSPantitrypsinGAAG-delta was prepared in the same manner as AVCBSP38GAAG-delta, using the *KpnI-HindIII* digestion product of the double-stranded DNA fragment with sequence 5'-C TGA GGTACC T GCC ACC-at gccgtcttct gtctcgtggg gcacccctct gctggcaggc ctgtgctgcc tggtcctgt ctcctggct-AAGCTT CGA T-3' (SEQ ID NO: 15) in lieu of fragment II. The resulting construct codes for a GAA peptide in which the hGAA leader sequence (SEQ ID NO: 4) has been replaced with the human ~~alpha-1-antitrypsin~~ alpha-1-antitrypsin leader sequence (~~SEQ ID NO: 7~~) (SEQ ID NO: 8).

AVCBSPALBGAAG-delta preparation strategy. AVCBSPALBGAAG-delta was prepared in the same manner as AVCBSP38GAAG-delta, using the *KpnI-HindIII* digestion product of the double-stranded DNA fragment with sequence 5'-C TGA GGTACC T GCC ACC-a tgaagtgggt aacctttatt tccctcttt ttctcttag ctcggcttat tcc-AAGCTT CGA T-3' (SEQ ID NO: 16) in lieu of fragment II. The resulting construct codes for a GAA peptide in which the hGAA leader sequence (SEQ ID NO: 4) has been replaced with the human albumin leader sequence (~~SEQ ID NO: 8~~) (SEQ ID NO: 7).

At page 81, line 18, amend Table 3 as follows.

Table 3. hGAA secretion with different leader sequences

Leader Sequence	Proportion hGAA Secreted (hGAA Medium/hGAA cells)	% Total hGAA secreted	Increased hGAA secretion (fold)
HGAA	0.53	34	N/A
SP38.1 <u>SP38</u>	9.7	91	18
Epo	1.1	53	2.1
α -1-antitrypsin	8.5	90	16
Factor IX	14	93	26